“…The Authors Reply We would like to thank Drs. Finsterer and Zarrouk-Mahjoub ( 1 ) for their interest in our recent publication in Internal Medicine regarding the enhanced risk of supraventricular arrhythmia in patients who are positive for anti-mitochondrial M2 (AMA-M2) antibodies ( 2 ). A key statement in their letter reads, “Overall, this interesting study could be more meaningful if a prospective design would have been applied, if more clinical data would have been collected, and if patients would have been more extensively investigated for cardiac disease”.…”